SR Pharma achieves key technical breakthrough with its lyophilized liposomal-based siRNA formulation
To date, the AtuRNAi and liposomal components of AtuRNAi drugs have needed to be separately lyophilized (freeze-dried), reconstituted and then combined, in a multi-step process. The new SR Pharma process enables siRNA drugs pre-formulated as liposomal nanoparticles to be freeze-dried and then simply reconstituted with water immediately prior to patient administration with no additional preparation steps such as sonication being required.
"This is a significant breakthrough in the manufacture of siRNA drugs. A dry powder formulation extends the shelf-life and simplifies the distribution chain, with the one-step reconstitution process enhancing ease of administration. We will be applying this technology to the manufacture of our products as we take our siRNA drugs forward towards the clinic," said Dr Klaus Giese, CSO of SR Pharma.
Other news from the department research and development
These products might interest you
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.